Journal ArticleDOI
Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.
TLDR
Platinum(IV) agents offer great potential in targeting, increasing efficacy, and decreasing toxicity of Platinum-based anticancer agents.Abstract:
Background: Intensive efforts have been implemented to improve the efficacy of platinum complexes
especially with emerging cisplatin resistance and elevated cancer deaths. Platinum(IV) agents show better pharmacokinetics
and decreased side effects compared to Platinum(II) agents.
Methods: This review aims to summarize and categorize the strategies being employed to improve the efficacy of
Platinum-based anticancer agents in recent years.
Results: Nanoparticles and nanoplatforms offer a vast variety of strategies in targeting specific tumor types and
delivering one or two lethal drugs simultaneously. Theranostic agents are being developed to achieve enhanced
imaging and provide further insight into the activity of platinum containing chemotherapy. Moreover, photoactivation
of Pt(IV) prodrugs specifically at the tumor site is gaining attention due to a controlled activity. A platinum
agent formulated as large multi-activity complex is the most common strategy being employed.
Conclusion: Platinum(IV) agents offer great potential in targeting, increasing efficacy, and decreasing toxicity of
Platinum-based anticancer agents. The strategies being employed are aiming to increase specificity and targeting
as well as provide more potent agents.read more
Citations
More filters
Journal ArticleDOI
Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?
Reece G. Kenny,Celine J. Marmion +1 more
TL;DR: This review has endeavored to showcase how a "multitargeted" approach to drug design has led to new families of metallodrugs which may not only reduce systemic toxicities associated with modern day chemotherapeutics but also address resistance issues that are plaguing many Chemotherapeutic regimens.
Journal ArticleDOI
Emerging platinum(IV) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment
TL;DR: This perspective focuses on various types of novel cisplatin-based Pt(iv) complexes, including Pt-loaded nanostructures, to overcome cisPlatin resistance and special attention will be devoted to complexes that target the tumor microenvironment, which is a new area for the development of effective Pt(IV) prodrugs.
Journal ArticleDOI
Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer.
TL;DR: HA-GEM/CH-Pt NPs could significantly enhance in vitro cytotoxicity and in vivo antitumor effect against lung cancer animal model compared to the single-drug-loaded NPs and free drug solutions.
Journal ArticleDOI
The prodrug approach in the era of drug design.
Anas Najjar,Rafik Karaman +1 more
TL;DR: Prodrugs are inactive precursors of an active drug designed to be bioconverted (activated) post administration with the main aim of improving the pharmacokinetic properties of the parent drug.
Journal ArticleDOI
Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands.
TL;DR: This review summarizes the recent progress in the development of Pt(IV) prodrugs conjugated with bioactive-targeting ligands, including histone deacetylase inhibitors, p53 agonists, alkylating agents, and nonsteroidal anti-inflammatory agents.